Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

Abstract
To the editor: Immune responses directed against epitopes derived from the mutated region of nucleophosmin 1 (NPM1) by NPM1 mut -specific CD8(+) cytotoxic T cells (CTLs) might be involved in the rejection of NPM1 mut myeloid leukemic blasts. NPM1 mutations are one of the most frequent molecular